Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-01025 in healthy subjects
NCT04730050Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing TT-01025 with Placebo (2 arms). Primary endpoint: Adverse Events at 30 days. Status: unknown.
02
Drugs
TT-01025
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04730050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730050.